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Abstract 
Network-based methods are playing an increasingly important role in drug design. Our main 
question in this paper was whether the efficiency of drug target proteins to spread perturbations in 
the human interactome is larger if the binding drugs have side effects, as compared to those 
which have no reported side effects. Our results showed that in general, drug targets were better 
spreaders of perturbations than non-target proteins, and in particular, targets of drugs with side 
effects were also better spreaders of perturbations than targets of drugs having no reported side 
effects in human protein-protein interaction networks. Colorectal cancer-related proteins were 
good spreaders and had a high centrality, while type 2 diabetes-related proteins showed an 
average spreading efficiency and had an average centrality in the human interactome. Moreover, 
the interactome-distance between drug targets and disease-related proteins was higher in diabetes 
than in colorectal cancer. Our results may help a better understanding of the network position and 
dynamics of drug targets and disease-related proteins, and may contribute to develop additional, 
network-based tests to increase the potential safety of drug candidates. 
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Introduction 
 
Due to the "curse of attrition" drug side effects are subjects of increasing concerns1-4. In recent 
years a growing number of side effect databases helped pharmacovigilance efforts2,5-10. In 
addition, the prediction of drug side effects was a subject of several excellent network studies. 
These contributions constructed and analyzed drug—side effect networks1,8,11, side effect 
similarity-based drug—drug networks12-14, drug target—side effect networks (including 
correlated drug binding profiles and side effect profiles and protein domain networks)3,5,7,15,16, as 
well as drug—side effect—biological pathway multi-layer networks9,10,17,18. 
 Parallel with the sequencing of the human genome, the pharmaceutical industry 
increasingly turned towards rational drug design, where drug target candidates are selected on the 
basis of known disease-related genes. In recent years, however, it became apparent that drug 
action often extends beyond its primary target, and also affects the neighbourhood of the primary 
target in molecular networks4,19-23. The influence on network neighbourhood can be efficiently 
modelled as a spreading process. Indeed, network spreading efficiency became increasingly used 
to characterize the dynamics of a wide variety of networks, such as the propagation of infections 
and computer viruses24-26, as well as the spread of information, innovations and social 
influence27-30. Long-range spread of conformational changes via protein-protein interaction 
networks is supported by several pieces of experimental evidence31,32. Moreover, recent studies 
extended the use of information-spread to molecular networks highlighting the usefulness of this 
approach in finding key amino acids of protein structure networks, biologically relevant changes 
of cellular functions upon stress, reprogramming biological networks, and uncovering the 
attractor changes in malignant transformation33-36. However, network spreading efficiency has 
been used to characterize drug targets neither in general, nor restricted to targets of drugs having 
side effects. 
 In this study we investigated, whether the efficiency of drug target proteins to spread 
perturbations in the human interactome is larger, if drugs targeting them have side effects, as 
compared to the spreading efficiency of targets of those drugs, which have no reported side 
effects. Encouraged by our findings that drug targets in general, and targets of drugs having side 
effects in particular, spread perturbation better in the human interactome than other proteins, we 
specifically examined two diseases, colorectal cancer and diabetes. These two, wide-spread 
diseases were selected, since they represent target groups of different drug design strategies4, and 
they had been the subjects of several former network-related studies37-45. We found that 
colorectal cancer-related proteins were good spreaders and had a high centrality in the human 
protein-protein interaction network. On the contrary, type 2 diabetes-related proteins showed an 
average spreading efficiency, and had an average centrality. Additionally, network shortest path 
(geodesic distance) between drug targets and disease-related proteins was higher in diabetes than 
in colorectal cancer. Our results give novel details on the network topology and dynamics of 
disease-related and drug target proteins, and may initiate the development of novel, network-
based pharmacovigilance methods increasing the potential safety of drug candidates. 
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Results 
Targets of drugs with side effects spread perturbations better in the human interactome 
than targets of drugs without side effects 
The initial working hypothesis of our research was that drugs having protein targets that better 
propagate changes in the human interactome may have a higher probability of causing side 
effects. This hypothesis is in agreement with earlier findings showing that the interactome 
neighbourhood contributed to drug side-effect similarity20. In order to test our hypothesis, we 
compared the propagation of perturbations started from drug targets with and without known side 
effect, as well as that of non-target proteins in the human protein-protein interaction network 
using the Turbine network dynamics software package developed earlier in our group35. 
 To compare the spreading efficiency of drug target proteins with and without side effects 
we ran a series of perturbation simulations on the human interactome using the Turbine 
programme35. We assembled a human interactome containing 12,439 proteins and 174,666 edges 
using the STRING database46, out of which 1,726 were target proteins of 3,626 human drugs 
obtained from the DrugBank database47 and a total of 99,423 drug-side effect pairs from the 
SIDER database2 were analysed as described in Methods in detail. Simulations were based on the 
communicating vessels network dynamics model tested earlier35, where changes from one protein 
to its neighbours 'flow' in proportion with the energy differences between the 'source' and the 
'target' proteins. We examined a total of 495 target proteins of 597 drugs (Suppl. Table 1), which 
were reported to have side effects according to the SIDER database2. As control groups, we have 
also examined the 1,231 target proteins of the remaining 3,029 drugs having no reported side 
effects in the SIDER database2, as well as the remaining 10,713 proteins in our human 
interactome, which were not listed as drug targets in DrugBank47. For each selected protein target 
we calculated the silencing time, which is the number of time steps in the simulation needed for 
the initial perturbation to disappear completely due to dissipation. Small silencing time values 
were shown to be an efficient measure of large spreading efficiency of network nodes earlier35, 
since in this case the initial perturbation efficiently spreads in the network and it becomes 
dissipated fast. 
Fig. 1 shows the cumulative distribution of the normalized number of proteins having an 
increasing silencing time (thus decreasing perturbation efficiency). Targets of drugs with side 
effects had a significantly larger proportion of small silencing times (i.e. large spreading 
efficiency) than targets of drugs having no side effects (Mann-Whitney-Wilcoxon test, 
p=1.677e-5). Similarly, the proportion of targets of drugs without side effects having a small 
silencing time (i.e. large spreading efficiency) was significantly larger than that of human 
interactome proteins, which have not been reported as drug targets in DrugBank47 (Mann-
Whitney-Wilcoxon test, p=2.2e-16). Thus targets of drugs with side effects were found to be 
better spreaders of perturbations than targets of drugs having no reported side effects. 
Importantly, drug targets were also better spreaders of perturbations than non-target proteins. 
 Simulations shown on Fig. 1 were run with a starting energy of 1,000 units and a 
dissipation value of 5 units. Being curious whether our result is robust for the variations of 
simulation parameters, we repeated these simulations using a starting energy of 10,000 and a 
dissipation of 1 or 5 units. Under these conditions we obtained very similar results (Suppl. Figs. 1 
and 2) to those shown on Fig. 1. When we split the starting energy of 1,000 units equally among 
targets of multi-target drugs instead of examining each target protein alone as the source of 
perturbations, we were able to reproduce the same pattern (Suppl. Fig. 3) as that of Fig. 1. 
Furthermore, to test the robustness of the results against the choice of protein-protein interaction 
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network, we randomly deleted 50% of the 12,439 proteins in our human interactome. Examining 
the spreading efficiency in the giant component of this truncated interactome we obtained very 
similar results (Suppl. Fig. 4) to those shown in Fig. 1. 
 Next we were curious whether the larger spreading efficiency of drug targets with side 
effects, as compared to drug targets without side effects or proteins having no reported drugs 
bound to them, is also shown by examining perturbation reach values. Perturbation reach values 
show the number of proteins, which received the perturbation from the initial perturbation source 
protein until the perturbation was dissipated from the system. Small perturbation reach values 
were shown to characterize small spreading efficiency in earlier studies35, since in this case the 
original perturbation reached only a small number of proteins before it became dissipated. 
Targets of drugs with side effects had a significantly smaller proportion of small perturbation 
reach values (i.e. small spreading efficiency) than that of targets of drugs having no side effects 
(Mann-Whitney-Wilcoxon test, p=1.663e-5; Suppl. Fig. 5). Similarly, the proportion of targets of 
drugs without side effects having a small perturbation reach value (i.e. small spreading 
efficiency) was significantly smaller than that of human interactome proteins, which have not 
been reported as drug targets in DrugBank47 (Mann-Whitney-Wilcoxon test, p=2.2e-16; Suppl. 
Fig. 5). Using a starting energy of 10,000 but a dissipation of 1 instead of 5 units, or splitting this 
starting energy equally among targets of multi-target drugs, we obtained very similar results 
(Suppl. Figs. 6 and 7). These studies confirmed that drug targets are better spreaders of 
perturbations than non-target proteins, and also that targets of drugs with side effects are better 
spreaders of perturbations than targets of drugs having no reported side effects. 
 A qualitatively similar picture emerged, when we examined the spreading efficiency of 
target proteins of drugs against two diseases, colorectal cancer and type 2 diabetes (Suppl. Tables 
2-6). We chose these two diseases, because they represent very well the target groups of different 
drug design strategies4, and they had been the subjects of several former network-related 
studies37-45. Drug targets of both diseases were found to be better spreaders of perturbations than 
non-target proteins (Suppl. Fig. 8; p=3.367e-5 and p=5.88e-5 for colorectal cancer and diabetes, 
respectively). There was a tendency showing that targets of drugs with side effects were better 
spreaders of perturbations than targets of drugs having no reported side effects both in colorectal 
cancer and in diabetes. However, due to the low number of identified drug targets having side 
effects (3 and 25, respectively), these latter differences were not statistically significant (p=1 and 
p=0.2593, respectively). 
Colorectal cancer-related proteins are good spreaders of perturbations and have a high 
centrality, while type-2 diabetes-related proteins show an average spreading efficiency and 
average centrality 
Very importantly, a rather interesting difference emerged, when we examined the spreading 
efficiency of proteins related to colorectal cancer and diabetes. Mutated genes and their 
corresponding proteins in colorectal cancer and in type-2 diabetes were obtained from the Cancer 
Gene Census database48 (Suppl. Table 7) and from the article of Parchwani et al.49 (Suppl. Table 
8), respectively. In case of colorectal cancer, disease-associated proteins were found to be 
significantly better spreaders than the residual proteins of the human interactome. On the 
contrary, diabetes-related proteins showed indistinguishable spreading properties to the rest of 
human proteins, which were not associated with the onset of diabetes (Fig. 2). To test the 
robustness of the results against the choice of protein-protein interaction network, we randomly 
deleted 50% of the 12,439 proteins in our human interactome. Here again, colorectal cancer-
associated proteins were found to be significantly better spreaders than the residual proteins of 
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the human interactome (data not shown; p=0.00021 in Mann-Whitney test) and spreading 
efficiency of diabetes-related proteins showed no significant difference as compared to the rest of 
human proteins (data not shown; p=0.095 in Mann-Whitney test). 
 These findings are in agreement with earlier results showing that cancer-associated 
proteins are enriched in proteins having a high centrality in the human interactome37,38,40,42-45. 
Indeed, in our human interactome, cancer-related proteins had a significantly higher degree, 
closeness and betweenness centralities than diabetes-related proteins, having a 9.6-, 1.2- and 54-
fold increase, respectively (Table 1).  In agreement with their similar silencing time values 
(Suppl. Fig. 8), drug targets without or with side effects showed no significant centrality 
differences in the human interactome (Suppl. Table 9). 
The interactome distance between drug targets and disease-related proteins is higher in 
diabetes than in colorectal cancer 
Encouraged by the results showing an increased centrality of cancer-related, but not of diabetes-
related proteins in the human interactome, we examined the interactome geodesic distance (i.e. 
shortest path) between drug targets and disease related proteins in both diseases using the 
neighbourhood matrices of related proteins. Our data show that the geodesic distance in the 
human interactome between drug targets and disease-related proteins is significantly larger in 
case of type-2 diabetes than in colorectal cancer (targets without side effects: p=1.062e-5; targets 
with side effects: p=5.441e-3). (Table 2; Suppl. Tables 10-13 and Suppl. Fig. 9) This finding is 
supported by the visual representation of the human sub-interactome of drug target and disease-
related proteins of these two diseases (Suppl. Fig. 10), where drug targets and disease-related 
proteins of colorectal cancer are intertwined, while these two groups of proteins remain rather 
separated in type-2 diabetes. This observation is further substantiated by the fact, that only 1 of 
the 18 colorectal cancer-related proteins (6%) is not connected to the giant component of the sub-
interactome, while 10 of the 14 diabetes-related proteins (71%) are missing from the same giant 
component (Suppl. Fig. 10). 
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Discussion 
 
The most important finding of our study is that 1.) drug targets are better spreaders of 
perturbations in the human interactome than non-target proteins in general; and in particular, 2.) 
targets of drugs with side effects are also better spreaders of perturbations than targets of drugs 
having no reported side effects (Fig. 1). These findings were robust, since they could be 
reproduced when we used different perturbation parameters (Suppl. Figs. 1, 2 and 3), different 
measures of perturbation spread (Suppl. Figs. 5, 6 and 7), and reduced the size (coverage) of the 
human interactome to half of the original (Suppl. Fig. 4). These results are in agreement with 
those of a previous study showing that the interactome neighbourhood contributed to side-effect 
similarity20. 
 Importantly, colorectal cancer-related proteins are good spreaders of perturbations and 
had a high centrality, while type-2 diabetes-related proteins showed an average spreading 
efficiency and had an average centrality in the human interactome (Fig. 2 and Table 1). These 
findings are in agreement with earlier results showing that cancer-associated proteins are 
enriched in hubs, bottlenecks and bridges all having a high centrality in the human 
interactome37,38,40,42-45. 
 Furthermore, the interactome-distance between drug targets and disease-related proteins 
was higher in diabetes than in colorectal cancer (Table 2; Suppl. Tables 10-13 and Suppl. Fig. 9). 
This finding is in agreement with both the results of previous studies and intuitive insights on the 
classification of drug target strategies4. Most drug targets are 3 or 4 steps away in the human 
interactome from proteins involved in the same disease50. Moreover, cancer-related and 
metabolic disease-related proteins were shown to have an average network distance to the related 
drug targets of 2.3 and ~5 network edges, which are smaller and higher than the most abundant 
distance values, respectively, forming the two extremes of the distance-spectrum50. The former 
value is in the range we found in our study (Table 2). The latter value of a disease group 
containing diabetes is much larger than that related to cancer, which is again in agreement with 
our findings. As a general trend, rapidly proliferating cells, like those in cancer, are attacked at 
their central proteins, while differentiated cells, such as those involved in type-2 diabetes, are 
attacked at the neighbours of central proteins4. These assumptions are also in agreement with a 
smaller network distance of centrally positioned cancer-related proteins from centrally positioned 
cancer drug targets than the distance between the more peripheral diabetes-related proteins and 
drug targets. 
 Analysis of perturbation spread in molecular networks may be used to develop additional, 
network-based tests to increase the potential safety of drug candidates. Assessment of 
perturbation spread in weighted networks (where the edges are weighted according to the 
abundance of their end-node proteins of relevant tissues, e.g. the endothelial cell in colorectal 
cancer, as well as hepatocyte and myocyte in diabetes, as described in our earlier study for the 
yeast interactome51), directed networks (such as signalling networks4,52), or networks considering 
the subcellular localization of participating proteins53, as well as using quantitative measures of 
side-effect severity and abundance may provide additional information and will be subjects of 
later studies. 
 In summary, our results contributed to a better understanding of the network position and 
dynamics of disease-related and drug target proteins. The findings may help the future 
development of novel, network-based pharmacovigilance methods increasing the potential safety 
of drug candidates. 
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Methods 
Construction of the human protein-protein interaction network 
In this paper, we examined the propagation of perturbations in the human protein-protein 
interaction network (interactome). The choice of this type of network was driven by the fact that 
it contains the most proteins and the greatest number of connections (as opposed to signalling 
networks or regulatory networks). Human interactome data were downloaded from the STRING 
database46 on 8 February, 2013. STRING contains interaction data based on a vast number of 
data collection principles. We have only used manually collected ('database' column) or 
experimental ('experiments' column) data having higher reliability than e.g. predicted data. Only 
human protein-protein interactions were included in the interactome. In order to facilitate the 
comparison with drug targets, the STRING Ensemble Protein ID (ENSP) protein codes were 
translated to UniProt ID54 using the UniProt translator. From the original 13,484 ENSP IDs we 
managed to translate 12,493 to UniProt IDs, but only 12,439 proteins were connected to other 
proteins. The database contained a total of 377,920 human protein-protein interactions, out of 
which 350,528 remained after translating the protein IDs to UniProt IDs using the UniProt 
translator, which were further reduced to 174,666 after eliminating multiple links and loops (self-
links). The original STRING database also contained edge weights indicating the reliability of 
data. Since we only worked with manually collected and experimental data, our interactome 
contained no edge weights. 
Measurement of the propagation of perturbations in the human interactome 
The propagation of perturbations in the human interactome was measured with the network 
perturbation analysis software for simulating network dynamics called Turbine35. For the 
simulation experiments we chose the software's communicating vessels model35, where changes 
from one protein to its neighbours 'flow' in proportion with the energy differences between the 
'source' and the 'target' proteins. The communicating vessels model35 contains a starting energy 
(E) and a dissipation parameter (D), where the starting energy is distributed equally among the 
proteins of the human interactome specified at the individual simulations, while in each step of 
the simulation the program subtracts D units of energy from each protein of the interactome. In 
most simulations E and D were set to 1000 and 5 units, respectively. Having these starting energy 
and dissipation parameters it was possible to trace the propagation of perturbations in the network 
rather easily. However, all the key simulations were also examined using different E and D 
values to examine the robustness of the results. To characterise the propagation efficiency of the 
starting node(s), the measure of silencing time35 was used, which is the time elapsed from the 
start of the simulation until the energy of all nodes reaches the minimum threshold of less than 1 
unit. We also calculated perturbation reach values35, which show the number of proteins 
receiving the perturbation from the initial perturbation source protein until the perturbation was 
dissipated from the system. 
Characterisation of drug side effects 
Drug side effects were collected from the SIDER database2. This database contains information 
about drug side effects and their frequencies from public documentation and package inserts, 
with the help of drug labels and terms from MedDRA (Medical Dictionary for Regulatory 
Activities). SIDER data were downloaded from the version of 17 October, 2012. This version of 
the SIDER database2 contained 996 drugs, 4,192 unique side effects and 215,850 drug-side effect 
pairs. After eliminating the duplicates, 99,423 drug-side effect pairs remained. In order to be able 
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to compare data, we converted drug IDs in the SIDER database2 into IDs of the DrugBank 
database47 by matching the drug names. 
Characterisation of drug targets 
We collected drug targets from the DrugBank database47 version last updated on 10 February, 
2013. The XML version of the database was used, including the drug names, indications and 
target list. The proteins in the target list were identified by their UniProt IDs54 with the help of the 
external reference table available in the database. From the drug target list only those drugs that 
targeted human proteins were selected. From the original 6,718 drugs 3,926 such drugs were 
found, of which 3,626 had target proteins contained in our human interactome. 
After comparison with the drug—side effect data from the SIDER database2, we found that 597 
drugs (with a total of 495 target proteins) had known side effects, while the remaining 3,029 
drugs (with 1,231 target proteins) had no reported side effects to date. 
Protein and drug target data related to the two examined diseases: colorectal cancer and 
type 2 diabetes 
Genes involved in colorectal cancer were collected from the Cancer Gene Census48 database, by 
selecting those proteins in the entire database that contained the word 'colorectal' in their 'Tumour 
Types' column. Genes related to type 2 diabetes were obtained from the article of Parchwani et 
al.49. The 18 genes involved in colorectal cancer and the 46 genes related to type 2 diabetes were 
then mapped to proteins marked by UniProt ID54 with the help of the Protein Identifier Cross-
Reference (PICR)55 application. See Suppl. Tables 7 and 8 for the genes and their respective 
proteins involved in the two diseases. From these proteins, all 18 colorectal cancer-related but 
only 14 type 2 diabetes-related were contained in our interactome. Drugs used in treatment of 
colorectal cancer and diabetes and their drug targets were collected based on the drug indications 
in the DrugBank database47. See Suppl. Table 2 for the relevant keywords used. We found 11 
drugs against colorectal cancer and 36 against type 2 diabetes, which all had valid targets. Drugs 
against colorectal cancer and type 2 diabetes had 33 and 42 target proteins, respectively, out of 
which 27 and 39, respectively, were contained in our human interactome. 
Other methods 
A number of Bash shell scripts were written to automate the network simulation experiments 
with Turbine. Statistical analysis of the results was performed with the R software package56. The 
Pajek software57 was used to measure geodesic distances and centralities in the human 
interactome, the Cytoscape software58 was used to create images of the human interactome and 
the Inkscape software59 was used to create some other images. 
 
Acknowledgments 
We thank members of the LINK-Group (www.linkgroup.hu) for helpful discussions. This work 
was supported by the Hungarian Scientific Research Fund [OTKA K83314]. T.K. was a grantee 
of the János Bolyai Scholarship of the Hungarian Academy of Sciences, and is supported by a 
fellowship in computational biology at The Genome Analysis Centre, in partnership with the 
Institute of Food Research, and strategically supported by BBSRC. 
  9
Author contributions 
P.C. initiated the project and conceived the research. A.R.P.L. performed all simulations and data 
analysis. D.T. and D.M. contributed in the assembly of databases. All (A.R.P.L., K.Z.S., D.T., 
D.M., K.L., T.K., P.C.) authors contributed to biological interpretation of the results. A.R.P.L. 
prepared the tables and figures. A.R.P.L. and P.C. wrote the manuscript text. All authors 
reviewed the manuscript. 
Competing financial interests: The supporters had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript. The authors declare no competing 
financial interests. 
 
References 
1. Fliri, A.F., Loging, W.T., Thadeio, P.F. & Volkmann, R.A. Analysis of drug-induced effect 
patterns to link structure and side effects of medicines. Nat. Chem. Biol. 1, 389-397 (2005). 
2. Kuhn, M., Campillos, M., Letunic, I., Jensen, L.J. & Bork, P. A side effect resource to capture 
phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010). 
3. Lounkine, E. et al. Large-scale prediction and testing of drug activity on side-effect targets. 
Nature 486, 361–367 (2012). 
4. Csermely, P., Korcsmáros, T., Kiss, H.J.M., London, G. & Nussinov, R. Structure and 
dynamics of molecular networks: A novel paradigm of drug discovery. Pharmacol. Ther. 
138, 333–408. (2013). 
5. Yang, L., Luo, H., Chen, J., Xing, Q. & He, L. SePreSA: a server for the prediction of 
populations susceptible to serious adverse drug reactions implementing the methodology of a 
chemical-protein interactome. Nucleic Acids Res. 37, W406–W412 (2009).  
6. Yang, L., Xu, L. & He, L. A CitationRank algorithm inheriting Google technology designed to 
highlight genes responsible for serious adverse drug reaction. Bioinformatics 25, 2244–2250 
(2009). 
7. Luo, H. et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse 
drug reactions via the chemical-protein interactome. Nucleic Acids Res. 39, W492–W498 
(2011). 
8. Oprea, T.I. et al. Associating drugs, targets and clinical outcomes into an integrated network 
affords a new platform for computer-aided drug repurposing. Mol. Inform. 30, 100–111 
(2011). 
9. Lopes, P. et al. Gathering and exploring scientific knowledge in pharmacovigilance. PLoS 
ONE 8, e83016 (2013). 
10. Oliveira, J.L. et al. The EU-ADR Web Platform: delivering advanced pharmacovigilance 
tools. Pharmacoepidemiol. Drug Saf. 22, 459–467 (2013). 
11. Garten, Y., Tatonetti, N.P. & Altman, R.B. Improving the prediction of pharmacogenes using 
text-derived drug-gene relationships. Pac. Symp. Biocomput. 305–314 (2010). 
12. Campillos, M., Kuhn, M., Gavin, A.C., Jensen, L.J. & Bork, P. Drug target identification 
using side-effect similarity. Science 321, 263–266 (2008). 
13. Yamanishi, Y., Kotera, M., Kanehisa, M., & Goto, S. Drug-target interaction prediction from 
chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 26, 
i246–i254 (2010). 
14. Takarabe, M., Okuda, S., Itoh, M., Tokimatsu, T., Goto, S. & Kanehisa, M. Network analysis 
of adverse drug interactions. Genome Inform. 20, 252–259 (2008).  
  10
15. Mizutani, S., Pauwels, E., Stoven, V., Goto, S. & Yamanishi, Y. Relating drug-protein 
interaction network with drug side effects. Bioinformatics 28, i522–i528 (2012). 
16. Iwata, H., Mizutani, S., Tabei, Y., Kotera, M., Goto, S. & Yamanishi Y. Inferring protein 
domains associated with drug side effects based on drug-target interaction network. BMC 
Syst. Biol. 7, S18 (2013). 
17. Lee, S., Lee, K.H., Song, M. & Lee, D. Building the process-drug-side effect network to 
discover the relationship between biological processes and side effects. BMC Bioinformatics 
12, S2 (2011).  
18. Bauer-Mehren, A. et al. Automatic filtering and substantiation of drug safety signals. PLoS 
Comput. Biol. 8, e1002457 (2012). 
19. Schwartz, J.M. & Nacher, J.C. Local and global modes of drug action in biochemical 
networks. BMC Chem. Biol. 9, 4 (2009). 
20. Brouwers, L., Iskar, M., Zeller, G., van Noort, V. & Bork, P. Network neighbors of drug 
targets contribute to drug side-effect similarity. PLoS ONE 6, e22187 (2011). 
21. Nussinov, R., Tsai, C.-J. & Csermely, P. Allo-network drugs: harnessing allostery in cellular 
networks. Trends Pharmacol. Sci, 32, 686–693 (2011). 
22. Wang, J., Li, Z.-X., Qiu, C-X., Wang, D. & Cui, Q-H. The relationship between rational drug 
design and drug side effects. Brief. Bioinform. 13, 377–382 (2012). 
23. Nacher, J.C. & Schwartz, J.M. Modularity in protein complex and drug interactions reveals 
new polypharmacological properties. PLoS ONE 7, e30028 (2012).  
24. Hu, H., Myers, S., Colizza, V. & Vespignani A. WiFi networks and malware epidemiology. 
Proc. Natl. Acad. Sci. USA 106, 1318–1323 (2009). 
25. Wang, P., González, M.C., Hidalgo, C.A. & Barabási, A.L. Understanding the spreading 
patterns of mobile phone viruses. Science 324, 1071–1076 (2009).  
26. Brockmann, D. & Helbing, D. The hidden geometry of complex, network-driven contagion 
phenomena. Science 342, 1337–1342 (2013). 
27. Zanette, D.H. Critical behavior of propagation on small-world networks. Phys. Rev. E 64, 
050901 (2001). 
28. Valente, T.W. Network interventions. Science 337, 49–53 (2012). 
29. Banerjee, A., Chandrasekhar, A.G., Duflo, E. & Jackson, M.O. The diffusion of 
microfinance. Science 341, 1236498 (2013). 
30. Aral, S. & Walker, D. Identifying influential and susceptible members of social networks. 
Science 337, 337–341 (2012). 
31. Bray, D. & Duke, T. Conformational spread: the propagation of allosteric states in large 
multiprotein complexes. Annu. Rev. Biophys. Biomol. Struct. 33, 53–73 (2004). 
32. Antal, M.A., Böde, C. & Csermely, P. Perturbation waves in proteins and protein networks: 
applications of percolation and game theories in signaling and drug design. Curr. Protein 
Pept. Sci. 10, 161–172 (2009). 
33. Stojmirović, A., Bliskovsky, A. & Yu, Y.K. CytoITMprobe: a network information flow 
plugin for Cytoscape. BMC Res. Notes 5, 237 (2012). 
34. Cornelius, S.P., Kath, W.L. & Motter, A.E. Realistic control of network dynamics. Nat. 
Commun. 4, 1942 (2013).  
35. Szalay, K.Z. & Csermely, P. Perturbation centrality and Turbine: A novel centrality measure 
obtained using a versatile network dynamics tool. PLoS ONE 8, e78059 (2013).  
36. Szalay, K.Z., Nussinov, R. & Csermely, P. Attractor structures of signaling networks: 
Consequences of different conformational barcode dynamics and their relations to network-
based drug design. Mol. Info. 33, 463–468 (2014). 
  11
37. Jonsson, P.F. & Bates, P.A. Global topological features of cancer proteins in the human 
interactome. Bioinformatics 22, 2291–2297 (2006). 
38. Chuang, H.Y., Lee, E., Liu, Y.T., Lee, D. & Ideker, T. Network-based classification of breast 
cancer metastasis. Mol. Syst. Biol. 3, 140 (2007). 
39. Hase, T., Tanaka, H., Suzuki, Y., Nakagawa, S. & Kitano, H. Structure of protein interaction 
networks and their implications on drug design. PLoS Comput. Biol. 5, e1000550 (2009). 
40. Taylor, I.W., et al. Dynamic modularity in protein interaction networks predicts breast cancer 
outcome. Nature Biotechn. 27, 199–204 (2009). 
41. Sharma, A., Chavali, S., Tabassum, R., Tandon, N. & Bharadwaj, D. Gene prioritization in 
type 2 diabetes using domain interactions and network analysis. BMC Genomics 11, 84 
(2010). 
42. Sun, J. & Zhao, Z. A comparative study of cancer proteins in the human protein-protein 
interaction network. BMC Genomics 11, S5 (2010). 
43. Rosado, J.O., Henriques, J.P., & Bonatto, D. A systems pharmacology analysis of major 
chemotherapy combination regimens used in gastric cancer treatment: predicting potential 
new protein targets and drugs. Curr. Cancer Drug Targets 11, 849–869 (2011). 
44. Xia, J., Sun, J., Jia, P. & Zhao, Z. Do cancer proteins really interact strongly in the human 
protein-protein interaction network? Comput. Biol. Chem. 35, 121–125 (2011). 
45. Serra-Musach, J. et al. Cancer develops, progresses and responds to therapies through 
restricted perturbation of the protein-protein interaction network. Integr. Biol. 4, 1038–1048 
(2012). 
46. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased 
coverage and integration. Nucleic Acids Res. 41, D808–D815 (2012). 
47. Knox, C. et al. DrugBank 3.0: a comprehensive resource for “omics” research on drugs. 
Nucleic Acids Res. 39, D1035–D1041 (2011). 
48. Forbes, S.A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic 
Mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2010). 
49. Parchwani, D., Murthy, S., Upadhyah, A. & Patel, D. Genetic factors in the etiology of type 2 
diabetes: linkage analyses, candidate gene association, and genome-wide association – still a 
long way to go! Natl. J. Physiol. Pharm. Pharmacol. 3, 57–68 (2013). 
50. Yildirim, M.A., Goh, K.-I., Cusick, M.E., Barabási, A.-L. & Vidal, M. Drug-target network. 
Nat. Biotechnol. 25, 1119–1126 (2007). 
51. Mihalik, Á. & Csermely, P. Heat shock partially dissociates the overlapping modules of the 
yeast protein-protein interaction network: a systems level model of adaptation. PLoS Comput. 
Biol. 7, e1002187 (2011). 
52. Fazekas, D. et al. SignaLink 2 – A signaling pathway resource with multi-layered regulatory 
networks. BMC Systems Biology 7, 7 (2013). 
53. Veres, D. et al. ComPPI: a cellular compartment-specific database for protein-protein 
interaction network analysis. Nucleic Acids Res. 43, D485-D493 (2015). 
54. The UniProt Consortium. Reorganizing the protein space at the Universal Protein Resource 
(UniProt). Nucleic Acids Res. 40, D71–D75 (2012). 
55. Wein, S.P. et al. Improvements in the Protein Identifier Cross-Reference service. Nucleic 
Acids Res. 40, W276–W280 (2012). 
56. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R 
Foundation for Statistical Computing. Available: http://www.R-project.org/ (2013). 
  12
57. Bagatelj, V. & Mrvar, A. Pajek - Analysis and Visualization of Large Networks. in Graph 
drawing software. Mathematics and visualization. (eds Jünger, M. & Mutzel, P.) 77–103 
(Springer, Berlin, 2003). 
58. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular 
interaction networks. Genome Res. 13, 2498–2504 (2003). 
59. The Inkscape Team. Inkscape. http://inkscape.org (2014). 
  13
 
Figure 1│Cumulative silencing time distribution of drug targets and non-target proteins. 
The diagram shows the cumulative distribution of the normalized number of proteins with given 
silencing times, which are drug targets with known side effects (blue dashed line), which are drug 
targets without known side effects (red solid line) and which are not drug targets (green dotted 
line). The number of proteins was normalized by dividing the number of proteins in each 
silencing time range by the total number of proteins allowing a better comparison. The total 
number of drug targets with and without side effects and non-target proteins was 495, 1,231 and 
10,713, respectively. The human interactome containing 12,439 proteins and 174,666 edges was 
built from the STRING database46, 1,726 human drug targets were obtained from the DrugBank 
database47 and 99,423 drug-side effect pairs were taken from the SIDER database2. Silencing 
times were calculated separately for every protein/drug target with the Turbine program35 as 
described in the Methods section using a starting energy of 1,000 and a dissipation value of 5 
units. Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) test 
function of the R package56. There was a statistically significant difference (p=1.677e-5) between 
the silencing times of drug targets with known side effects and the silencing times of drug targets 
without reported side effects. The difference between the silencing times of drug targets and non-
target proteins was also statistically significant (p=2.2e-16). 
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Figure 2│Cumulative silencing time distribution of colorectal cancer- and type 2 diabetes 
mellitus-related proteins, as well as proteins, which are not related to these diseases. The 
diagram shows the cumulative distribution of the normalized number of proteins with given 
silencing times, which are related to the disease (red line), as well as those, which are not related 
to the disease (green dotted line); for colorectal cancer (Panel A) and type 2 diabetes (Panel B). 
The number of proteins was normalized by dividing the number of proteins in each silencing time 
range by the total number of proteins allowing a better comparison. The total number of 
colorectal cancer-related proteins and type 2 diabetes-related proteins in the human interactome 
was 18 and 14, respectively. The human interactome containing 12,439 proteins and 174,666 
edges was built from the STRING database46. Colorectal cancer- and type 2 diabetes-related 
proteins were obtained from the Cancer Gene Census database48 and from the article of 
Parchwani et al.49, respectively. Silencing times were calculated separately for every protein with 
the Turbine program35 as described in the Methods section using a starting energy of 1,000 and a 
dissipation value of 5 units. Statistical analysis was performed using the Mann-Whitney 
(Wilcoxon rank sum) test function of the R package56. There was a statistically significant 
difference between the silencing times of disease-related and non-related proteins in case of 
colorectal cancer (p=2.329e-9) and but there was none in case of type 2 diabetes (p=0.8343). 
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Table 1│Average human interactome centralities of proteins related to colorectal cancer 
and type 2 diabetes 
Disease-related proteins Proteins, which are not related to 
any of the two diseases 
Centrality 
type 
Colorectal 
cancer 
Type 2 
diabetes 
Statistical 
difference 
between 
cancer- and 
diabetes-
related 
proteins 
Centrality 
value 
Statistical 
difference 
from 
values of 
cancer-
related 
proteins 
Statistical 
difference 
from 
values of 
diabetes-
related 
proteins 
Degree 
(number of 
neighbours) 
159.5 9.000 7.09e-5 9.000 2.58e-9 0.830 
Closeness 
centrality 
(1/edge) 
0.357 0.294 3.46e-5 0.277 1.90e-10 0.122 
Betweenness 
centrality 
(fraction of 
shortest paths 
passing through 
the node) 
2.55e-3 1.16e-5 1.24e-4 1.34e-5 3.23e-9 0.922 
The table shows the medians of the centralities of proteins related to colorectal cancer and type 2 
diabetes (results were very similar, if instead of medians we used their arithmetic means; data not 
shown). The total number of colorectal cancer- and type 2 diabetes-related proteins was 18 and 
14, respectively. Centrality values were calculated with the Pajek programme57. The human 
interactome containing 12,439 proteins and 174,666 edges was built from the STRING 
database46. Colorectal cancer-related proteins were obtained from the Cancer Gene Census 
database48, type 2 diabetes-related proteins were obtained from the article of Parchwani et al.49. 
Statistical analysis was performed using the Wilcoxon rank sum (Mann-Whitney) test function of 
the R package56. 
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Table 2│Average network distance of drug targets without and with known side effects 
used in the treatment of colorectal cancer and type 2 diabetes from the disease-associated 
proteins 
Protein group 
Average network distance 
from disease-related proteins 
(edges) 
24 drug targets without known side effects 
used in the treatment of colorectal cancer 2.528 
3 drug targets with known side effects used 
in the treatment of colorectal cancer 2.389 
14 drug targets without known side effects 
used in the treatment of type 2 diabetes 3.250* 
25 drug targets with known side effects 
used in the treatment of type 2 diabetes 3.234** 
*This value is significantly greater than the average network distance of drug targets without known side 
effects in colorectal cancer (p=1.062e-05). Statistical analysis was performed using the Welch (Student’s) 
two sample t-test function of the R package56. 
**This value is significantly greater than the average network distance of drug targets with known side 
effects in colorectal cancer (p=0.005441). Statistical analysis was performed using the Welch (Student’s) 
two sample t-test function of the R package56. 
The table shows the arithmetic mean of the average network distance between drug targets (with 
and without known side effects used in the treatment of colorectal cancer and type 2 diabetes) 
and the proteins related to the respective disease (results were very similar, if instead of 
arithmetic means we used the medians; data not shown). The total number of colorectal cancer- 
and diabetes-related proteins in the human interactome were 18 and 14, respectively. Average 
network distances were calculated as shortest paths using the Pajek programme58. Proteins were 
labelled by their UniProt ID54. Human interactome containing 12,439 proteins and 174,666 edges 
was built from the STRING database46, 1,726 human drug targets were obtained from the 
DrugBank database47 and 99,423 drug-side effect pairs were taken from the SIDER database2. 
Colorectal cancer- and type 2 diabetes-related proteins were obtained from the Cancer Gene 
Census database48 and from the article of Parchwani et al.49, respectively. We used the mean 
values and the t-test because of the near-normal distribution of the average network distances. 
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Figure 1│Cumulative silencing time distribution of drug targets and non-target proteins 
with a starting energy of 10,000 and a dissipation value of 5. The diagram shows the 
cumulative distribution of the normalized number of proteins with given silencing times, which 
are drug targets with known side effects (blue dashed line), which are drug targets without 
known side effects (red solid line) and which are not drug targets (green dotted line). The 
number of proteins was normalized by dividing the number of proteins in each silencing time 
range by the total number of proteins allowing a better comparison. The total number of drug 
targets with and without side effects, and non-target proteins was 495, 1,231 and 10,713, 
respectively. The figure shows the 99.99% of all proteins (having a silencing time below 1500). 
The human interactome containing 12,439 proteins and 174,666 edges was built from the 
STRING database1, 1,726 human drug targets were obtained from the DrugBank database2 and 
99,423 drug-side effect pairs were taken from the SIDER database3. Silencing times were 
calculated separately for every protein with the Turbine program4 as described in the Methods 
section of the main text with a starting energy of 10,000 and a dissipation value of 5 units. 
Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) test function of 
the R package5. There was a statistically significant difference (p=1.701e-5) between the 
silencing times of drug targets with known side effects and the silencing times of drug targets 
without known side effects. The difference between the silencing times of drug targets and non-
target proteins was also statistically significant (p=2.2e-16). 
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Figure 2│Cumulative silencing time distribution of drug targets and non-target proteins 
with a starting energy of 10,000 and a dissipation value of 1. The diagram shows the 
cumulative distribution of the normalized number of proteins with given silencing times, which 
are drug targets with known side effects (blue dashed line), which are drug targets without 
known side effects (red solid line) and which are not drug targets (green dotted line). The 
number of proteins was normalized by dividing the number of proteins in each silencing time 
range by the total number of proteins allowing a better comparison. The total number of drug 
targets with and without side effects, and non-target proteins was 495, 1,231 and 10,713, 
respectively. The figure shows 99.61% of all proteins (having a silencing time below 4000). The 
human interactome containing 12,439 proteins and 174,666 edges was built from the STRING 
database1, 1,726 human drug targets were obtained from the DrugBank database2 and 99,423 
drug-side effect pairs were taken from the SIDER database3. Silencing times were calculated 
separately for every protein with the Turbine program4 as described in the Methods section of the 
main text with a starting energy of 10,000 and a dissipation value of 1 unit. Statistical analysis 
was performed using the Mann-Whitney (Wilcoxon rank sum) test function of the R package5. 
There was a statistically significant difference (p=9.635e-6) between the silencing times of drug 
targets with known side effects and the silencing times of drug targets without known side 
effects. The difference between the silencing times of drug targets and non-target proteins was 
also statistically significant (p=2.2e-16). 
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Figure 3│Cumulative silencing time distribution of drugs and non-target proteins with 
starting energy of 1,000 and a dissipation value of 5 with distributed starting energy among 
multiple targets. The diagram shows the cumulative silencing time distribution of the 
normalized number of drugs with known side effects (blue dashed line), drugs without known 
side effects (red solid line) and non-target proteins (green dotted line). The number of 
proteins/drugs was normalized by dividing the number of proteins/drugs in each silencing time 
range by the total number of proteins/drugs allowing a better comparison. The total number of 
drugs with and without side effects, and non-target proteins was 597, 3,029 and 10,713, 
respectively. The human interactome containing 12,439 proteins and 174,666 edges was built 
from the STRING database1, 3,626 human drugs were obtained from the DrugBank database2 
and 99,423 drug-side effect pairs were taken from the SIDER database3. Silencing times were 
calculated separately for every protein/drug with the Turbine program4 as described in the 
Methods section of the main text with a starting energy of 1000 and a dissipation value of 5 
units. In case of drugs with multiple targets, the starting energy was distributed evenly among the 
drug targets. Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) 
test function of the R package5. There was a statistically significant difference (p=2.2e-16) 
between the silencing times of drugs with known side effects and the silencing times of drugs 
without known side effects. The difference between the silencing times of drugs and non-target 
proteins was also statistically significant (p=2.2e-16). 
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Figure 4│Cumulative silencing time distribution of drug target proteins and non-target 
proteins with a starting energy of 1000 and a dissipation value of 5 using a 50% smaller 
interactome. The diagram shows the cumulative distribution of the normalized number of 
proteins with given silencing times, which are drug targets with known side effects (blue dashed 
line), which are drug targets without known side effects (red solid line) and which are not drug 
targets (green dotted line). The number of proteins was normalized by dividing the number of 
proteins in each silencing time range by the total number of proteins allowing a better 
comparison. The total number of drug targets with and without side effects, and non-target 
proteins was 495, 1,231 and 10,713, respectively. The human interactome containing 12,439 
proteins and 174,666 edges was built from the STRING database1, 1,726 human drug targets 
were obtained from the DrugBank database2 and 99,423 drug-side effect pairs were taken from 
the SIDER database3. 50% of the original interactome proteins were deleted randomly. The giant 
component of the remaining interactome contained 5,549 proteins (45%), 806 drug target 
proteins total (47%) and 232 drug targets with known side effects (47%). Silencing times were 
calculated separately for every protein with the Turbine program4 as described in the Methods 
section of the main text with a starting energy of 1,000 and a dissipation value of 5 units. 
Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) test function of 
the R package5. There was a statistically significant difference (p=3.368e-4) between the 
silencing times of drug targets with known side effects and the silencing times of drug targets 
without known side effects. The difference between the silencing times of drug targets and non-
target proteins was also statistically significant (p=2.2e-16). 
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Figure 5│Cumulative perturbation reach distribution of drug targets and non-target 
proteins with a starting energy of 10,000 and a dissipation value of 5. The diagram shows the 
cumulative distribution of the normalized number of proteins with given perturbation reach 
values, which are drug targets with known side effects (blue dashed line), which are drug targets 
without known side effects (red solid line) and which are not drug targets (green dotted line). 
The number of proteins was normalized by dividing the number of proteins in each perturbation 
reach range by the total number of proteins allowing a better comparison. The total number of 
drug targets with and without side effects, and non-target proteins was 495, 1,231 and 10,713, 
respectively. The figure shows 97.25% of all proteins (having a perturbation reach below 200 
proteins reached). The human interactome containing 12,439 proteins and 174,666 edges was 
built from the STRING database1, 1,726 human drug targets were obtained from the DrugBank 
database2 and 99,423 drug-side effect pairs were taken from the SIDER database3. Perturbation 
reach values were calculated separately for every protein with the Turbine program4 as described 
in the Methods section of the main text with a starting energy of 10,000 and a dissipation value 
of 5 units. Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) test 
function of the R package5. There was a statistically significant difference (p=1.663e-5) between 
the perturbation reach values of drug targets with known side effects and the perturbation reach 
values of drug targets without known side effects. The difference between the perturbation reach 
values of drug targets and non-target proteins was also statistically significant (p=2.2e-16). 
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Figure 6│Cumulative perturbation reach distribution of drug targets and non-target 
proteins with a starting energy of 10,000 and a dissipation value of 1. The diagram shows the 
cumulative distribution of the normalized number of proteins with given perturbation reach 
values, which are drug targets with known side effects (blue dashed line), which are drug targets 
without known side effects (red solid line) and which are not drug targets (green dotted line). 
The number of proteins was normalized by dividing the number of proteins in each perturbation 
reach range by the total number of proteins allowing a better comparison. The total number of 
drug targets with and without side effects, and non-target proteins was 495, 1,231 and 10,713, 
respectively. The figure shows 97.25% of all proteins (having a perturbation reach below 200 
proteins reached). The human interactome containing 12,439 proteins and 174,666 edges was 
built from the STRING database1, 1,726 human drug targets were obtained from the DrugBank 
database2 and 99,423 drug-side effect pairs were taken from the SIDER database3. Perturbation 
reach values were calculated separately for every protein with the Turbine program4 as described 
in the Methods section of the main text with a starting energy of 10,000 and a dissipation value 
of 1 unit. Statistical analysis was performed using the Mann-Whitney (Wilcoxon rank sum) test 
function of the R package5. There was a statistically significant difference (p=1.49e-5) between 
the perturbation reach values of drug targets with known side effects and the perturbation reach 
values of drug targets without known side effects. The difference between the perturbation reach 
values of drug targets and non-target proteins was also statistically significant (p=2.2e-16). 
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Figure 7│Cumulative perturbation reach distribution of drugs and non-target proteins 
with starting energy of 10,000 and a dissipation value of 1 with distributed starting energy 
among multiple targets. The diagram shows the cumulative perturbation reach distribution of 
the normalized number of drugs with known side effects (blue dashed line), drugs without 
known side effects (red solid line) and non-target proteins (green dotted line). The number of 
proteins/drugs was normalized by dividing the number of proteins/drugs in each perturbation 
reach range by the total number of proteins/drugs allowing a better comparison. The total 
number of drugs with and without side effects, and non-target proteins was 597, 3,029 and 
10,713, respectively. The figure shows 99.58% of all proteins/drugs (having a perturbation reach 
below 400 proteins reached). The human interactome containing 12,439 proteins and 174,666 
edges was built from the STRING database1, 3,626 human drugs were obtained from the 
DrugBank database2 and 99,423 drug-side effect pairs were taken from the SIDER database3. 
Perturbation reach values were calculated separately for every protein/drug with the Turbine 
program4 as described in the Methods section of the main text with a starting energy of 10,000 
and a dissipation value of 1 unit. In case of drugs with multiple targets, the starting energy was 
distributed evenly among the drug targets. Statistical analysis was performed using the Mann-
Whitney (Wilcoxon) test function of the R package5. There was a statistically significant 
difference (p=6.176e-8) between the perturbation reach values of drugs with known side effects 
and the perturbation reach values of drugs without known side effects. The difference between 
the perturbation reach values of drugs and non-target proteins was also statistically significant 
(p=2.2e-16). 
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Figure 8│Cumulative silencing time distribution of targets of drugs used in the treatment 
of colorectal cancer and type 2 diabetes mellitus. The diagram shows the cumulative 
distribution of the normalized number of proteins with given silencing times, which are drug 
targets used in the treatment of the disease with known side effects (blue dashed line), which are 
drug targets used in the treatment of the disease without known side effects (red solid line) and 
which are not drug targets (green dotted line); for colorectal cancer (Panel A) and type 2 diabetes 
(Panel B). The number of proteins was normalized by dividing the number of proteins in each 
silencing time range by the total number of proteins allowing a better comparison. The total 
number of drug targets used in the treatment of colorectal cancer with and without side effects 
was 3 and 24, respectively, while for type 2 diabetes the total number of drug targets was 25 and 
14, respectively. The human interactome containing 12,439 proteins and 174,666 edges was built 
from the STRING database1, 1,726 human drug targets were obtained from the DrugBank 
database2 and 99,423 drug-side effect pairs were taken from the SIDER database3. Silencing 
times were calculated separately for every protein with the Turbine program4 as described in the 
Methods section of the main text with a starting energy of 1,000 and a dissipation value of 5 
units. Statistical analysis was performed using the Mann-Whitney-Wilcoxon test of the R 
package5. No statistically significant difference could be shown between silencing times of 
targets with known side effects and silencing times of targets without known side effects of 
drugs used in the treatment of colorectal cancer (p=1) and type 2 diabetes (p=0.2593). However, 
the difference between the silencing times of drug targets and non-target proteins was 
statistically significant for drug targets used in the treatment of both colorectal cancer (p=3.367e-
5) and type 2 diabetes (p=5.88e-5). 
  11
 
 
Figure 9│Human interactome distance between drug targets used in the treatment of 
colorectal cancer and type 2 diabetes, between proteins related to these diseases and 
randomly selected proteins. The figure shows the average human interactome distances 
between the following proteins: drug targets used in the treatment of colorectal cancer and type 2 
diabetes with and without side effects (orange circles), proteins related to these diseases (green 
circles) and randomly selected proteins (blue circles). The sides of the triangles (the distance 
between the centres of the circles) are proportional to the average number of human interactome 
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edges between the respective protein groups, while the vertical lines associated with the sides of 
the triangles correspond to the standard deviation (SD). The average distance between randomly 
selected proteins and disease-related proteins was 2.82 edges (SD: 0.601) for colorectal cancer 
and 3.43 edges (SD: 0.557) for type 2 diabetes; between randomly selected proteins and drug 
targets with side effects was 3.24 edges (SD: 0.551) for colorectal cancer and 3.44 edges (SD: 
0.490) for type 2 diabetes; between randomly selected proteins and drug targets without side 
effects was 3.32 edges (SD: 0.533) for colorectal cancer and 3.41 edges (SD: 0.545) for type 2 
diabetes; between disease-related proteins and drug targets with side effects was 2.39 edges (SD: 
0.242) for colorectal cancer and 3.23 edges (SD: 0.522) for type 2 diabetes; between disease-
related proteins and drug targets without side effects was 2.53 edges (SD: 0.388) for colorectal 
cancer and 3.25 edges (SD: 0.402) for type 2 diabetes. Sizes of the circles are proportional to the 
number of proteins contained in each group. There were 50 randomly selected proteins; 18 
colorectal cancer-related and 14 type 2 diabetes-related proteins; 3 drug targets with and 24 drug 
targets without side effects used in the treatment of colorectal cancer; 25 drug targets with and 14 
drug targets without side effects used in the treatment of type 2 diabetes. The human interactome 
containing 12,439 proteins and 174,666 edges was built from the STRING database1, 1,726 
human drug targets were obtained from the DrugBank database2 and 99,423 drug-side effect 
pairs were taken from the SIDER database3. Network distances were calculated as shortest paths 
using the Pajek programme6 as described in the Methods section of the main text and are detailed 
in Tables 10-13. The figure was created using Inkscape7. 
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Figure 10│Human protein-protein interaction network of the proteins related to colorectal 
cancer and type 2 diabetes and the drug targets used in the treatment of these diseases. The 
figure shows the giant component of the human protein-protein interaction network containing 
the proteins related to colorectal cancer and type 2 diabetes mellitus and the drug targets used in 
the treatment of these diseases. Red nodes represent proteins or drug targets related to colorectal 
cancer, blue nodes represent those related to type 2 diabetes, while purple nodes represent those 
related to both. Ellipses, octagons and squares represent proteins related to diseases, drug targets 
without known side effects and drug targets with known side effects, respectively. Node 
highlighted by green box (a.) is the TCF7L2 protein related to both diseases, which is the 
transcription factor 7-like 2 participating in the Wnt signalling pathway and modulating MYC 
expression. The highly interconnected node cluster highlighted by green box (b.) contains 11 
drug targets without known side effects used in the treatment of colorectal cancer, which are all 
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tubuline chain proteins. Node highlighted by green box (c.) representing protein GLP1R, the 
glucagon-like peptide 1 receptor, is connected only to node TUBB3 of the tubuline cluster (b.). 
The highly interconnected node cluster highlighted by green box (d.) contains 5 drug targets with 
known side effects used in the treatment of type 2 diabetes which are the  peroxisome 
proliferator-activated receptors alpha (PPARA), gamma (PPARG) and delta (PPARD) and the 
estrogen-related receptors alpha (ESRRA) and gamma (ESSRG). The network hub highlighted 
by green box (e.) is TP53, the cellular tumour antigen p53. Node sizes are proportional to the 
degrees of the respective proteins in the full human protein-protein interaction network. All 
proteins here are referenced by their UniProt ID9. The human interactome containing 12,439 
proteins and 174,666 edges was built from the STRING database1, 1,726 human drug targets 
were obtained from the DrugBank database2 and 99,423 drug-side effect pairs were taken from 
the SIDER database3. Node degrees were calculated with the Pajek programme6 as described in 
the Methods section of the main text. The figure was created using Cytoscape8 and Inkscape7. 
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Supplementary Tables 
Table 1│Drugs obtained from the DrugBank database, which have known side effects in 
the SIDER database 
DBID Drug Name 
DB00001 Lepirudin 
DB00006 Bivalirudin 
DB00046 Insulin Lispro 
DB00047 Insulin Glargine 
DB00050 Cetrorelix 
DB00063 Eptifibatide 
DB00106 Abarelix 
DB00115 Cyanocobalamin 
DB00125 L-Arginine 
DB00152 Thiamine 
DB00162 Vitamin A 
DB00175 Pravastatin 
DB00176 Fluvoxamine 
DB00177 Valsartan 
DB00178 Ramipril 
DB00180 Flunisolide 
DB00182 Amphetamine 
DB00184 Nicotine 
DB00185 Cevimeline 
DB00186 Lorazepam 
DB00187 Esmolol 
DB00188 Bortezomib 
DB00191 Phentermine 
DB00193 Tramadol 
DB00195 Betaxolol 
DB00197 Troglitazone 
DB00198 Oseltamivir 
DB00200 Hydroxocobalamin 
DB00201 Caffeine 
DB00202 Succinylcholine 
DB00204 Dofetilide 
DB00205 Pyrimethamine 
DB00206 Reserpine 
DB00208 Ticlopidine 
DBID Drug Name 
DB00210 Adapalene 
DB00211 Midodrine 
DB00213 Pantoprazole 
DB00214 Torasemide 
DB00215 Citalopram 
DB00216 Eletriptan 
DB00218 Moxifloxacin 
DB00222 Glimepiride 
DB00227 Lovastatin 
DB00228 Enflurane 
DB00231 Temazepam 
DB00240 Alclometasone 
DB00242 Cladribine 
DB00243 Ranolazine 
DB00246 Ziprasidone 
DB00247 Methysergide 
DB00248 Cabergoline 
DB00252 Phenytoin 
DB00253 Medrysone 
DB00257 Clotrimazole 
DB00264 Metoprolol 
DB00268 Ropinirole 
DB00273 Topiramate 
DB00276 Amsacrine 
DB00277 Theophylline 
DB00278 Argatroban 
DB00280 Disopyramide 
DB00281 Lidocaine 
DB00282 Pamidronate 
DB00284 Acarbose 
DB00285 Venlafaxine 
DB00286 Conjugated Estrogens 
DB00287 Travoprost 
DB00288 Amcinonide 
DBID Drug Name 
DB00289 Atomoxetine 
DB00292 Etomidate 
DB00293 Raltitrexed 
DB00295 Morphine 
DB00296 Ropivacaine 
DB00297 Bupivacaine 
DB00302 Tranexamic Acid 
DB00307 Bexarotene 
DB00308 Ibutilide 
DB00310 Chlorthalidone 
DB00312 Pentobarbital 
DB00313 Valproic Acid 
DB00315 Zolmitriptan 
DB00316 Acetaminophen 
DB00317 Gefitinib 
DB00318 Codeine 
DB00320 Dihydroergotamine 
DB00321 Amitriptyline 
DB00323 Tolcapone 
DB00324 Fluorometholone 
DB00327 Hydromorphone 
DB00328 Indomethacin 
DB00331 Metformin 
DB00332 Ipratropium bromide 
DB00333 Methadone 
DB00334 Olanzapine 
DB00335 Atenolol 
DB00337 Pimecrolimus 
DB00338 Omeprazole 
DB00343 Diltiazem 
DB00344 Protriptyline 
DB00346 Alfuzosin 
DB00349 Clobazam 
DB00350 Minoxidil 
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DBID Drug Name 
DB00351 Megestrol 
DB00356 Chlorzoxazone 
DB00357 Aminoglutethimide 
DB00358 Mefloquine 
DB00360 Tetrahydrobiopterin 
DB00361 Vinorelbine 
DB00363 Clozapine 
DB00364 Sucralfate 
DB00367 Levonorgestrel 
DB00368 Norepinephrine 
DB00370 Mirtazapine 
DB00371 Meprobamate 
DB00373 Timolol 
DB00374 Treprostinil 
DB00376 Trihexyphenidyl 
DB00377 Palonosetron 
DB00379 Mexiletine 
DB00380 Dexrazoxane 
DB00381 Amlodipine 
DB00382 Tacrine 
DB00384 Triamterene 
DB00388 Phenylephrine 
DB00390 Digoxin 
DB00393 Nimodipine 
DB00396 Progesterone 
DB00398 Sorafenib 
DB00401 Nisoldipine 
DB00404 Alprazolam 
DB00408 Loxapine 
DB00411 Carbachol 
DB00412 Rosiglitazone 
DB00413 Pramipexole 
DB00418 Secobarbital 
DB00419 Miglustat 
DB00421 Spironolactone 
DB00422 Methylphenidate 
DB00423 Methocarbamol 
DB00425 Zolpidem 
DBID Drug Name 
DB00431 Lindane 
DB00433 Prochlorperazine 
DB00434 Cyproheptadine 
DB00437 Allopurinol 
DB00439 Cerivastatin 
DB00440 Trimethoprim 
DB00441 Gemcitabine 
DB00444 Teniposide 
DB00446 Chloramphenicol 
DB00448 Lansoprazole 
DB00449 Dipivefrin 
DB00450 Droperidol 
DB00454 Meperidine 
DB00457 Prazosin 
DB00458 Imipramine 
DB00459 Acitretin 
DB00461 Nabumetone 
DB00462 Methylscopolamine 
DB00465 Ketorolac 
DB00471 Montelukast 
DB00472 Fluoxetine 
DB00474 Methohexital 
DB00475 Chlordiazepoxide 
DB00476 Duloxetine 
DB00477 Chlorpromazine 
DB00480 Lenalidomide 
DB00481 Raloxifene 
DB00482 Celecoxib 
DB00484 Brimonidine 
DB00486 Nabilone 
DB00489 Sotalol 
DB00490 Buspirone 
DB00491 Miglitol 
DB00492 Fosinopril 
DB00494 Entacapone 
DB00496 Darifenacin 
DB00497 Oxycodone 
DB00499 Flutamide 
DBID Drug Name 
DB00500 Tolmetin 
DB00501 Cimetidine 
DB00502 Haloperidol 
DB00518 Albendazole 
DB00519 Trandolapril 
DB00521 Carteolol 
DB00530 Erlotinib 
DB00532 Mephenytoin 
DB00533 Rofecoxib 
DB00535 Cefdinir 
DB00537 Ciprofloxacin 
DB00539 Toremifene 
DB00540 Nortriptyline 
DB00541 Vincristine 
DB00542 Benazepril 
DB00543 Amoxapine 
DB00545 Pyridostigmine 
DB00547 Desoximetasone 
DB00548 Azelaic Acid 
DB00549 Zafirlukast 
DB00550 Propylthiouracil 
DB00554 Piroxicam 
DB00555 Lamotrigine 
DB00558 Zanamivir 
DB00559 Bosentan 
DB00561 Doxapram 
DB00563 Methotrexate 
DB00564 Carbamazepine 
DB00571 Propranolol 
DB00572 Atropine 
DB00573 Fenoprofen 
DB00575 Clonidine 
DB00580 Valdecoxib 
DB00585 Nizatidine 
DB00586 Diclofenac 
DB00590 Doxazosin 
DB00591 Fluocinolone Acetonide
DB00593 Ethosuximide 
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DBID Drug Name 
DB00594 Amiloride 
DB00598 Labetalol 
DB00602 Ivermectin 
DB00603 Medroxyprogesterone 
DB00605 Sulindac 
DB00608 Chloroquine 
DB00611 Butorphanol 
DB00612 Bisoprolol 
DB00615 Rifabutin 
DB00619 Imatinib 
DB00620 Triamcinolone 
DB00621 Oxandrolone 
DB00622 Nicardipine 
DB00623 Fluphenazine 
DB00624 Testosterone 
DB00630 Alendronate 
DB00631 Clofarabine 
DB00633 Dexmedetomidine 
DB00635 Prednisone 
DB00640 Adenosine 
DB00641 Simvastatin 
DB00642 Pemetrexed 
DB00647 Propoxyphene 
DB00650 Leucovorin 
DB00651 Dyphylline 
DB00652 Pentazocine 
DB00654 Latanoprost 
DB00656 Trazodone 
DB00659 Acamprosate 
DB00661 Verapamil 
DB00665 Nilutamide 
DB00668 Epinephrine 
DB00669 Sumatriptan 
DB00672 Chlorpropamide 
DB00673 Aprepitant 
DB00674 Galantamine 
DB00675 Tamoxifen 
DB00678 Losartan 
DBID Drug Name 
DB00679 Thioridazine 
DB00680 Moricizine 
DB00683 Midazolam 
DB00685 Trovafloxacin 
DB00687 Fludrocortisone 
DB00690 Flurazepam 
DB00691 Moexipril 
DB00692 Phentolamine 
DB00694 Daunorubicin 
DB00695 Furosemide 
DB00696 Ergotamine 
DB00697 Tizanidine 
DB00700 Eplerenone 
DB00703 Methazolamide 
DB00704 Naltrexone 
DB00706 Tamsulosin 
DB00708 Sufentanil 
DB00710 Ibandronate 
DB00712 Flurbiprofen 
DB00714 Apomorphine 
DB00715 Paroxetine 
DB00720 Clodronate 
DB00721 Procaine 
DB00724 Imiquimod 
DB00727 Nitroglycerin 
DB00728 Rocuronium 
DB00731 Nateglinide 
DB00733 Pralidoxime 
DB00734 Risperidone 
DB00735 Naftifine 
DB00740 Riluzole 
DB00745 Modafinil 
DB00747 Scopolamine 
DB00749 Etodolac 
DB00750 Prilocaine 
DB00751 Epinastine 
DB00753 Isoflurane 
DB00754 Ethotoin 
DBID Drug Name 
DB00757 Dolasetron 
DB00758 Clopidogrel 
DB00762 Irinotecan 
DB00763 Methimazole 
DB00764 Mometasone 
DB00768 Olopatadine 
DB00772 Malathion 
DB00773 Etoposide 
DB00774 Hydroflumethiazide 
DB00775 Tirofiban 
DB00776 Oxcarbazepine 
DB00780 Phenelzine 
DB00782 Propantheline 
DB00783 Estradiol 
DB00784 Mefenamic acid 
DB00788 Naproxen 
DB00790 Perindopril 
DB00794 Primidone 
DB00795 Sulfasalazine 
DB00796 Candesartan 
DB00798 Gentamicin 
DB00799 Tazarotene 
DB00800 Fenoldopam 
DB00802 Alfentanil 
DB00804 Dicyclomine 
DB00806 Pentoxifylline 
DB00807 Proparacaine 
DB00808 Indapamide 
DB00809 Tropicamide 
DB00810 Biperiden 
DB00811 Ribavirin 
DB00813 Fentanyl 
DB00814 Meloxicam 
DB00818 Propofol 
DB00819 Acetazolamide 
DB00822 Disulfiram 
DB00829 Diazepam 
DB00831 Trifluoperazine 
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DBID Drug Name 
DB00834 Mifepristone 
DB00835 Brompheniramine 
DB00836 Loperamide 
DB00838 Clocortolone 
DB00839 Tolazamide 
DB00841 Dobutamine 
DB00842 Oxazepam 
DB00843 Donepezil 
DB00844 Nalbuphine 
DB00850 Perphenazine 
DB00851 Dacarbazine 
DB00857 Terbinafine 
DB00860 Prednisolone 
DB00861 Diflunisal 
DB00863 Ranitidine 
DB00864 Tacrolimus 
DB00868 Benzonatate 
DB00869 Dorzolamide 
DB00870 Suprofen 
DB00871 Terbutaline 
DB00872 Conivaptan 
DB00873 Loteprednol 
DB00876 Eprosartan 
DB00881 Quinapril 
DB00883 Isosorbide Dinitrate 
DB00884 Risedronate 
DB00887 Bumetanide 
DB00889 Granisetron 
DB00896 Rimexolone 
DB00897 Triazolam 
DB00898 Ethanol 
DB00899 Remifentanil 
DB00900 Didanosine 
DB00903 Ethacrynic acid 
DB00904 Ondansetron 
DB00905 Bimatoprost 
DB00906 Tiagabine 
DB00907 Cocaine 
DBID Drug Name 
DB00908 Quinidine 
DB00909 Zonisamide 
DB00910 Paricalcitol 
DB00912 Repaglinide 
DB00915 Amantadine 
DB00918 Almotriptan 
DB00920 Ketotifen 
DB00921 Buprenorphine 
DB00924 Cyclobenzaprine 
DB00925 Phenoxybenzamine 
DB00927 Famotidine 
DB00929 Misoprostol 
DB00933 Mesoridazine 
DB00937 Diethylpropion 
DB00938 Salmeterol 
DB00949 Felbamate 
DB00952 Naratriptan 
DB00953 Rizatriptan 
DB00959 Methylprednisolone 
DB00960 Pindolol 
DB00961 Mepivacaine 
DB00962 Zaleplon 
DB00963 Bromfenac 
DB00964 Apraclonidine 
DB00966 Telmisartan 
DB00968 Methyldopa 
DB00969 Alosetron 
DB00973 Ezetimibe 
DB00975 Dipyridamole 
DB00978 Lomefloxacin 
DB00979 Cyclopentolate 
DB00980 Ramelteon 
DB00981 Physostigmine 
DB00983 Formoterol 
DB00986 Glycopyrrolate 
DB00988 Dopamine 
DB00989 Rivastigmine 
DB00990 Exemestane 
DBID Drug Name 
DB00991 Oxaprozin 
DB00992 Methyl aminolevulinate
DB00993 Azathioprine 
DB00996 Gabapentin 
DB00997 Doxorubicin 
DB00998 Frovatriptan 
DB00999 Hydrochlorothiazide 
DB01001 Salbutamol 
DB01005 Hydroxyurea 
DB01006 Letrozole 
DB01009 Ketoprofen 
DB01012 Cinacalcet 
DB01013 Clobetasol 
DB01014 Balsalazide 
DB01017 Minocycline 
DB01018 Guanfacine 
DB01019 Bethanechol 
DB01023 Felodipine 
DB01024 Mycophenolic acid 
DB01029 Irbesartan 
DB01030 Topotecan 
DB01032 Probenecid 
DB01035 Procainamide 
DB01036 Tolterodine 
DB01037 Selegiline 
DB01039 Fenofibrate 
DB01041 Thalidomide 
DB01043 Memantine 
DB01047 Fluocinonide 
DB01050 Ibuprofen 
DB01057 Echothiophate 
DB01059 Norfloxacin 
DB01062 Oxybutynin 
DB01064 Isoproterenol 
DB01067 Glipizide 
DB01068 Clonazepam 
DB01069 Promethazine 
DB01073 Fludarabine 
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DBID Drug Name 
DB01076 Atorvastatin 
DB01079 Tegaserod 
DB01083 Orlistat 
DB01085 Pilocarpine 
DB01086 Benzocaine 
DB01087 Primaquine 
DB01088 Iloprost 
DB01091 Butenafine 
DB01095 Fluvastatin 
DB01097 Leflunomide 
DB01098 Rosuvastatin 
DB01100 Pimozide 
DB01101 Capecitabine 
DB01104 Sertraline 
DB01105 Sibutramine 
DB01106 Levocabastine 
DB01109 Heparin 
DB01110 Miconazole 
DB01114 Chlorpheniramine 
DB01115 Nifedipine 
DB01118 Amiodarone 
DB01119 Diazoxide 
DB01120 Gliclazide 
DB01122 Ambenonium 
DB01126 Dutasteride 
DB01128 Bicalutamide 
DB01129 Rabeprazole 
DB01130 Prednicarbate 
DB01132 Pioglitazone 
DB01133 Tiludronate 
DB01136 Carvedilol 
DB01142 Doxepin 
DB01143 Amifostine 
DB01148 Flavoxate 
DB01149 Nefazodone 
DB01151 Desipramine 
DB01156 Bupropion 
DB01157 Trimetrexate 
DBID Drug Name 
DB01158 Bretylium 
DB01159 Halothane 
DB01161 Chloroprocaine 
DB01162 Terazosin 
DB01165 Ofloxacin 
DB01167 Itraconazole 
DB01169 Arsenic trioxide 
DB01173 Orphenadrine 
DB01174 Phenobarbital 
DB01177 Idarubicin 
DB01182 Propafenone 
DB01183 Naloxone 
DB01184 Domperidone 
DB01185 Fluoxymesterone 
DB01186 Pergolide 
DB01189 Desflurane 
DB01193 Acebutolol 
DB01194 Brinzolamide 
DB01195 Flecainide 
DB01196 Estramustine 
DB01197 Captopril 
DB01198 Zopiclone 
DB01200 Bromocriptine 
DB01202 Levetiracetam 
DB01203 Nadolol 
DB01204 Mitoxantrone 
DB01205 Flumazenil 
DB01206 Lomustine 
DB01210 Levobunolol 
DB01214 Metipranolol 
DB01215 Estazolam 
DB01216 Finasteride 
DB01217 Anastrozole 
DB01218 Halofantrine 
DB01219 Dantrolene 
DB01220 Rifaximin 
DB01221 Ketamine 
DB01222 Budesonide 
DBID Drug Name 
DB01223 Aminophylline 
DB01224 Quetiapine 
DB01226 Mivacurium 
DB01229 Paclitaxel 
DB01233 Metoclopramide 
DB01234 Dexamethasone 
DB01236 Sevoflurane 
DB01238 Aripiprazole 
DB01241 Gemfibrozil 
DB01242 Clomipramine 
DB01247 Isocarboxazid 
DB01248 Docetaxel 
DB01250 Olsalazine 
DB01254 Dasatinib 
DB01258 Aliskiren 
DB01260 Desonide 
DB01261 Sitagliptin 
DB01267 Paliperidone 
DB01268 Sunitinib 
DB01273 Varenicline 
DB01275 Hydralazine 
DB01276 Exenatide 
DB01278 Pramlintide 
DB01280 Nelarabine 
DB01291 Pirbuterol 
DB01306 Insulin Aspart 
DB01320 Fosphenytoin 
DB01327 Cefazolin 
DB01337 Pancuronium 
DB01340 Cilazapril 
DB01356 Lithium 
DB01364 Ephedrine 
DB01367 Rasagiline 
DB01373 Calcium 
DB01378 Magnesium 
DB01393 Bezafibrate 
DB01394 Colchicine 
DB01399 Salsalate 
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DBID Drug Name 
DB01400 Neostigmine 
DB01406 Danazol 
DB01409 Tiotropium 
DB01410 Ciclesonide 
DB01427 Amrinone 
DB01558 Bromazepam 
DB01577 Methamphetamine 
DB01586 Ursodeoxycholic acid 
DB01591 Solifenacin 
DB01595 Nitrazepam 
DB01611 Hydroxychloroquine 
DB01612 Amyl Nitrite 
DB01618 Molindone 
DBID Drug Name 
DB01621 Pipotiazine 
DB01623 Thiothixene 
DB02300 Calcipotriol 
DB04835 Maraviroc 
DB04839 Cyproterone 
DB04844 Tetrabenazine 
DB04845 Ixabepilone 
DB04861 Nebivolol 
DB04868 Nilotinib 
DB04896 Milnacipran 
DB04930 Permethrin 
DB05246 Methsuximide 
DB05271 Rotigotine 
DBID Drug Name 
DB06209 Prasugrel 
DB06228 Rivaroxaban 
DB06274 Alvimopan 
DB06287 Temsirolimus 
DB06335 Saxagliptin 
DB06695 Dabigatran etexilate 
DB06698 Betahistine 
DB06699 Degarelix 
DB06700 Desvenlafaxine 
DB06702 Fesoterodine 
DB06710 Methyltestosterone 
DB06711 Naphazoline 
DB06802 Nepafenac 
Drugs were obtained from the DrugBank database2, and their side effects were collected from the 
SIDER database3. 
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Table 2│The keywords used in the filtering of the DrugBank database and their 
occurrences 
Keyword Mark Occurrences 
„cancer”/ 
„lymphoma”/ 
„carcinoma”/ 
„leukemia”/ 
„tumor” 
Anti-cancer 172 
„colon”/ 
„colorectal”/ 
„carcinoma”/ 
„cancer”/ 
„tumor” 
Anti-colorectal 
cancer 11 
„diabetes mellitus” Anti-diabetes 36 
The keywords are listed which were used in the filtering of the DrugBank database2 and their 
occurrences is noted. The plus sign (+) represents the “AND” logical operator, the slash (/) 
represents the “OR” logical operator. 
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Table 3│Drugs obtained from the DrugBank database, which are used in the treatment of 
colorectal cancer and have no reported side effects in the SIDER database and their target 
proteins 
DrugBank ID Drug Name Drug Target Proteins 
DB00002 Cetuximab O75015, P00533, P00736, P02745, P02746, P02747, P09871, P12314, P12318, P31994 
DB00112 Bevacizumab O75015, P00736, P02745, P02746, P02747, P12314, P12318, P31994 
DB00113 Arcitumomab P13688 
DB00544 Fluorouracil P04818 
DB00848 Levamisole P10696, P32297 
DB01269 Panitumumab P00533 
DB01873 Epothilone D P04350, P07437, P68363, P68366, P68371, Q13509, Q13748, Q71U36, Q9BQE3, Q9H4B7, Q9NY65 
Drugs and their targets were obtained from the DrugBank database2. Only those drugs were 
selected, which are used in the treatment of colorectal cancer and have no reported side effects in 
the SIDER database3. Target proteins for each drug were identified by their UniProt ID9. 
  23
Table 4│Drugs obtained from the DrugBank database, which are used in the treatment of 
colorectal cancer and have known side effects in the SIDER database and their target 
proteins 
Drugbank ID Drug Name Drug Target Proteins 
DB00650 Leucovorin P04818 
DB00762 Irinotecan P11387 
DB01101 Capecitabine P04818 
DB01157 Trimetrexate P00374 
Drugs and their targets were obtained from the DrugBank database2. Only those drugs were 
selected, which are used in the treatment of colorectal cancer and have known side effects in the 
SIDER database3. Target proteins for each drug were identified by their UniProt ID9. 
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Table 5│Drugs obtained from the DrugBank database, which are used in the treatment of 
type 2 diabetes and have no reported side effects in the SIDER database and their target 
proteins 
DrugBank ID Drug Name Drug Target Proteins 
DB00030 Insulin recombinant P06213, P06400, P07339, P08069, P14735, P16519, P16870, P29120, P48745, P98164, Q16270, Q96C24 
DB00071 Insulin, porcine 
P01906, P06213, P06400, P07339, P08069, P14735, 
P16519, P16870, P29120, P48745, P98164, Q16270, 
Q96C24 
DB00414 Acetohexamide P48048 
DB00722 Lisinopril P12821, Q9BYF1 
DB00914 Phenformin Q13131, Q15842 
DB01124 Tolbutamide P48048, Q09428 
DB01251 Gliquidone Q09428, Q15842 
DB01289 Glisoxepide Q09428, Q15842 
DB01307 Insulin Detemir P06213 
DB01309 Insulin Glulisine P06213 
DB01382 Glycodiazine P48048, Q09428 
DB04876 Vildagliptin P27487 
DB06655 Liraglutide P43220 
Drugs and their targets were obtained from the DrugBank database2. Only those drugs were 
selected, which are used in the treatment of type 2 diabetes and have no reported side effects in 
the SIDER database3. Target proteins for each drug were identified by their UniProt ID9. 
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Table 6│Drugs obtained from the DrugBank database, which are used in the treatment of 
type 2 diabetes and have known side effects in the SIDER database and their target 
proteins 
Drugbank ID Drug Name Drug Target Proteins 
DB00046 Insulin Lispro P06213, P08069 
DB00047 Insulin Glargine P06213, P08069 
DB00178 Ramipril P12821 
DB00197 Troglitazone O60488, P05121, P11474, P37231, P62508, Q99808 
DB00222 Glimepiride P48048, Q09428, Q14654 
DB00412 Rosiglitazone O60488, P37231 
DB00491 Miglitol P10253, Q14697, Q8TET4 
DB00492 Fosinopril P12821 
DB00519 Trandolapril P12821 
DB00731 Nateglinide P37231, Q09428 
DB00834 Mifepristone P04150, P06401 
DB00839 Tolazamide P48048 
DB00881 Quinapril P12821 
DB00912 Repaglinide P37231, Q09428 
DB00966 Telmisartan P30556, P37231 
DB01067 Glipizide P37231, Q09428 
DB01132 Pioglitazone P37231 
DB01261 Sitagliptin P27487 
DB01276 Exenatide P43220 
DB01278 Pramlintide O60894, O60895, O60896 
DB01306 Insulin Aspart P06213 
DB01393 Bezafibrate P37231, Q03181, Q07869 
DB06335 Saxagliptin P27487 
Drugs and their targets were obtained from the DrugBank database2. Only those drugs were 
selected, which are used in the treatment of type 2 diabetes and have known side effects in the 
SIDER database3. Target proteins for each drug were identified by their UniProt ID9. 
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Table 7│Mutated genes in colorectal cancer and their corresponding proteins 
Gene name Protein identifier 
AKT1 P31749 
APC P25054 
BRAF P15056 
CTNNB1 P35222 
EP300 Q09472 
FBXW7 Q969H0 
KRAS P01116 
MADH4 Q13485 
MAP2K4 P45985 
MDM2 Q00987 
MLH1 P40692 
MSH2 P43246 
MSH6 P52701 
PIK3CA P42336 
PIK3R1 P27986 
TCF7L2 Q9NQB0 
TP53 P04637 
VTI1A Q96AJ9 
The 18 mutated genes in colorectal cancer were obtained from the Cancer Gene Census10 and the 
proteins coded by them were mapped by PICR11. 
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Table 8│Mutated genes in type 2 diabetes and their corresponding proteins 
Gene name Protein identifier 
ABCC8 Q54P13 
CAPN10 Q9HC96 
HNF1B Q91910 
GCGR P30082 
TCF7L2 Q9NQB0* 
PPARG O18924 
KCNJ11 O02822 
WFS1 P56695 
HNF1B Q91910 
SLC30A8 Q5I020 
HHEX D2KQB0 
CDKAL1 Q5VV42* 
IGF2BP2 Q9Y6M1* 
CDKN2A O77617 
CDKN2B P42772* 
FTO Q9C0B1* 
JAZF1 Q80ZQ5 
CDC123 A6R687 
CAMK1D Q8IU85* 
TSPAN8 Q2KIS9 
LGR5 Q9Z1P4 
THADA A8C752 
ADAMTS9 Q9P2N4 
NOTCH2 Q04721* 
Gene name Protein identifier 
KCNQ1 P51787* 
IRS1 Q28224 
MTNR1B Q8CIQ6 
PROX1 P48437 
GCKR Q07071 
ADCY5 P30803 
UBE2E2 Q96LR5* 
BCL11A Q9H165* 
GCKR Q07071 
DGKB Q9Y6T7* 
TMEM195 A0JPQ8 
C2CD4B A6NLJ0 
KLF14 Q9ESX2 
ZBED3 Q96IU2 
TP53INP1 Q96A56* 
CHCHD9 Q5T1J5 
CENTD2 Q4LDD4 
HMGA2 P52926* 
HNF1A Q90867 
PRC1 Q94JQ6 
ZFAND6 Q9DCH6 
DUSP9 Q99956* 
The 46 mutated genes in type 2 diabetes were obtained from the article of Parchwani et al.12 and 
the proteins coded by them were mapped by PICR10. From the 46 proteins listed here only 14 
were contained in the human interactome constructed from the STRING database1; those are 
marked with an asterisk (*) in the Table. 
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Table 9│Average human interactome centralities of target proteins of drugs against 
colorectal cancer and type 2 diabetes 
Drug targets without side effects Drug targets with side effects Centrality 
type Colorectal cancer 
Type 2 
diabetes 
Statistical 
difference
Colorectal 
cancer 
Type 2 
diabetes 
Statistical 
difference
Degree 
(number of 
neighbours) 
24.50 13.00 0.203 40.00 34.00 0.941 
Closeness 
centrality 
(1/edge) 
0.305 0.295 0.330 0.301 0.292 0.572 
Betweenness 
centrality 
(fraction of 
shortest paths 
passing through 
the node) 
1.46E-4 5.76E-4 0.601 3.39E-4 1.28E-4 0.944 
The table shows the medians of the centralities of target proteins of drugs against colorectal 
cancer and type 2 diabetes without or with reported side effects (the results were very similar, if 
instead of medians we used the arithmetic means; data not shown). Centrality values were 
calculated with the Pajek programme6. The human interactome containing 12,439 proteins and 
174,666 edges was built from the STRING database1, 1,726 human drug targets were obtained 
from the DrugBank database2, and the proteins were labelled by their UniProt ID9.  99,423 drug-
side effect pairs were taken from the SIDER database3. Statistical analysis was performed using 
the Wilcoxon rank sum (Mann-Whitney) test function of the R package5. 
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Table 10│Average network distance between drug targets without known side effects used 
in the treatment of colorectal cancer and colorectal cancer-associated proteins 
UniProt ID of colorectal cancer drug targets 
without side effects 
Average network distance from 
colorectal cancer-related proteins 
(edges) 
O75015 2.500 
P00533 1.722 
P00736 2.722 
P02745 2.889 
P02746 3.000 
P02747 3.000 
P04350 2.278 
P07437 2.167 
P09871 3.000 
P10696 3.222 
P12314 2.722 
P12318 2.444 
P13688 2.444 
P31994 2.500 
P32297 3.056 
P68363 2.111 
P68366 2.000 
P68371 2.444 
Q13509 2.722 
Q13748 2.111 
Q71U36 2.111 
Q9BQE3 2.389 
Q9H4B7 2.778 
Q9NY65 2.333 
Mean network distance of drug targets 2.528 
Mean network distance of randomly selected proteins 3.316 
The table shows the average network distance between drug targets without known side effects used in 
the treatment of colorectal cancer and colorectal cancer-related proteins. The total number of drug targets 
without known side effects used in the treatment of colorectal cancer was 24; the total number of 
colorectal cancer-related proteins was 18. Average network distances were calculated as shortest paths 
using the Pajek programme6. Proteins were labelled by their UniProt ID9. The human interactome 
containing 12,439 proteins and 174,666 edges was built from the STRING database1, 1,726 human drug 
targets were obtained from the DrugBank database2 and 99,423 drug-side effect pairs were taken from the 
SIDER database3. Colorectal cancer-related proteins were obtained from the Cancer Gene Census 
database10. Average network distances between colorectal cancer-related proteins and at least 50 
randomly selected samples of 24 proteins each were calculated, and the statistical difference in their mean 
values compared to the average network distance of the 24 drug targets listed above was tested using the 
one-way ANOVA (Analysis of Variance) with linear model fit function of the R package5. There was no 
statistically significant difference between the mean values of the drug targets without known side effects 
and the random samples, F=0.8807, p=0.7078. 
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Table 11│Average network distance between drug targets with known side effects used in 
the treatment of colorectal cancer and colorectal cancer-associated proteins 
UniProt ID of colorectal cancer drug targets with 
side effects 
Average network distance from 
colorectal cancer-related proteins 
(edges) 
P00374 2.500 
P04818 2.556 
P11387 2.111 
Mean network distance of drug targets 2.389 
Mean network distance of randomly selected proteins 3.240 
The table shows the average network distance between drug targets with known side effects used 
in the treatment of colorectal cancer and colorectal cancer-related proteins. The total number of 
drug targets with known side effects used in the treatment of colorectal cancer was 3; the total 
number of colorectal cancer-related proteins was 18. Average network distances were calculated 
as shortest paths using the Pajek programme6. Proteins were labelled by their UniProt ID9. The 
human interactome containing 12,439 proteins and 174,666 edges was built from the STRING 
database1, 1,726 human drug targets were obtained from the DrugBank database2 and 99,423 
drug-side effect pairs were taken from the SIDER database3. Colorectal cancer-related proteins 
were obtained from the Cancer Gene Census database10. Average network distances between 
colorectal cancer related proteins and at least 50 randomly selected samples of 3 proteins each 
were calculated, and the statistical difference in their mean values compared to the average 
network distance of the 3 drug targets listed above was tested using the one-way ANOVA 
(Analysis of Variance) with linear model fit function of the R package5. There was no 
statistically significant difference between the mean values of the drug targets with known side 
effects and the random samples, F=1.223, p=0.1951. 
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Table 12│Average network distance between drug targets without known side effects used 
in the treatment of type 2 diabetes and diabetes-associated proteins 
UniProt ID of type 2 diabetes drug targets without 
side effects 
Average network distance from 
diabetes-related proteins (edges) 
P01906 3.786 
P06400 2.286 
P07339 3.000 
P14735 3.214 
P16519 3.786 
P16870 3.286 
P29120 3.143 
P48745 3.214 
P98164 3.000 
Q13131 2.929 
Q15842 3.714 
Q16270 3.143 
Q96C24 3.500 
Q9BYF1 3.500 
Mean network distance of drug targets 3.250 
Mean network distance of randomly selected proteins 3.413 
The table shows the average network distance between drug targets without known side effects 
used in the treatment of type 2 diabetes and diabetes-related proteins. The total number of drug 
targets without known side effects used in the treatment of type 2 diabetes was 14; the total 
number of type 2 diabetes-related proteins contained in the human interactome was 14. Average 
network distances were calculated as shortest paths using the Pajek programme6. Proteins were 
labelled by their UniProt ID9. The human interactome containing 12,439 proteins and 174,666 
edges was built from the STRING database1, 1,726 human drug targets were obtained from the 
DrugBank database2 and 99,423 drug-side effect pairs were taken from the SIDER database3. 
Type 2 diabetes-related proteins were obtained from the article of Parchwani et al.12. Average 
network distances between type-2 diabetes related proteins and at least 50 randomly selected 
samples of 14 proteins each were calculated, and the statistical difference in their mean values 
compared to the average network distance of the 14 drug targets listed above was tested using the 
one-way ANOVA (Analysis of Variance) with linear model fit function of the R package5. There 
was no statistically significant difference between the mean values of the drug targets without 
known side effects and the random samples, F=0.7867, p=0.8547. 
  32
Table 13│Average network distance between drug targets with known side effects used in 
the treatment of type 2 diabetes and diabetes-associated proteins 
UniProt ID of type 2 diabetes drug targets with side 
effects 
Average network distance from 
diabetes-related proteins (edges) 
O60488 3.643 
O60894 3.857 
O60895 3.857 
O60896 3.429 
P04150 2.429 
P05121 2.857 
P06213 2.643 
P06401 2.500 
P08069 2.571 
P10253 3.786 
P11474 3.000 
P12821 3.786 
P27487 3.500 
P30556 3.000 
P37231 2.643 
P43220 3.071 
P48048 3.214 
P62508 3.071 
Q03181 2.857 
Q07869 2.714 
Q09428 3.500 
Q14654 3.286 
Q14697 3.357 
Q8TET4 3.929 
Q99808 4.357 
Mean network distance of drug targets 3.234 
Mean network distance of randomly selected proteins 3.443 
The table shows the average network distance between drug targets with known side effects used in the 
treatment of type 2 diabetes and diabetes-related proteins. The total number of drug targets with known 
side effects used in the treatment of type 2 diabetes was 25; the total number of type 2 diabetes-related 
proteins contained in the human interactome was 14. Average network distances were calculated as 
shortest paths using the Pajek programme6. Proteins were labelled by their UniProt ID9. The human 
interactome containing 12,439 proteins and 174,666 edges was built from the STRING database1, 1,726 
human drug targets were obtained from the DrugBank database2 and 99,423 drug-side effect pairs were 
taken from the SIDER database3. Type 2 diabetes-related proteins were obtained from the article of 
Parchwani et al.12. Average network distances between type-2 diabetes related proteins and at least 50 
randomly selected samples of 25 proteins each were calculated, and the statistical difference in their mean 
values compared to the average network distance of the 25 drug targets listed above was tested using the 
one-way ANOVA (Analysis of Variance) with linear model fit function of the R package5. There was no 
statistically significant difference between the mean values of the drug targets with known side effects 
and the random samples, F= 0.9021, p= 0.6677. 
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